BACKGROUND: Supraventricular tachyarrhythmia is a common problem in chronic obstructive pulmonary disease (COPD) patients. The purpose of this study is to analyze the factors associated with paroxysmal atrial fibrillation (AF) in COPD patients. METHODS: Forty COPD patients (38 male, 2 female, mean age 60 +/- 9 years) and 33 healthy controls (29 male, 4 female, mean age: 58 +/- 10 years) were included in this study. Echocardiography, 24-hour ambulatory and 12-lead ECG, pulmonary function tests, arterial blood gases, and serum electrolytes were measured. On ECG, maximum (P(max)) and minimum (P(min)) duration of P wave and its difference, P-wave dispersion (PWd), were measured. RESULTS: On echocardiography, diastolic dysfunction was found in 14 of the 40 (35%) COPD patients. Heart rate variability analysis revealed that COPD patients had decreased SDANN, SDNN, SDNNIDX in time-domain, and decreased LF in frequency domain parameters. Fourteen of the 40 COPD patients (35%) had AF. Patients with AF were older (57 +/- 10 vs 64 +/- 5 years, P = 0.03) and had lower SDANN, SDNN, and LF/HF ratio as compared to patients without AF in univariate analysis. All P-wave intervals (P(max), P(min,) and PWd) were increased in COPD patients compared to controls. P-wave dispersion was significantly increased in COPD patients with AF, as compared to patients without AF (57 +/- 11 vs 44 +/- 7 ms, P = 0.001). In logistic regression analysis PWd was found to be the only factor associated with the development of AF (P = 0.04). CONCLUSIONS: The presence of AF was significantly related to the prolongation of PWd, but not with pulmonary function, arterial blood gasses, and left and right atrial function.
BACKGROUND:Supraventricular tachyarrhythmia is a common problem in chronic obstructive pulmonary disease (COPD) patients. The purpose of this study is to analyze the factors associated with paroxysmal atrial fibrillation (AF) in COPDpatients. METHODS: Forty COPDpatients (38 male, 2 female, mean age 60 +/- 9 years) and 33 healthy controls (29 male, 4 female, mean age: 58 +/- 10 years) were included in this study. Echocardiography, 24-hour ambulatory and 12-lead ECG, pulmonary function tests, arterial blood gases, and serum electrolytes were measured. On ECG, maximum (P(max)) and minimum (P(min)) duration of P wave and its difference, P-wave dispersion (PWd), were measured. RESULTS: On echocardiography, diastolic dysfunction was found in 14 of the 40 (35%) COPDpatients. Heart rate variability analysis revealed that COPDpatients had decreased SDANN, SDNN, SDNNIDX in time-domain, and decreased LF in frequency domain parameters. Fourteen of the 40 COPDpatients (35%) had AF. Patients with AF were older (57 +/- 10 vs 64 +/- 5 years, P = 0.03) and had lower SDANN, SDNN, and LF/HF ratio as compared to patients without AF in univariate analysis. All P-wave intervals (P(max), P(min,) and PWd) were increased in COPDpatients compared to controls. P-wave dispersion was significantly increased in COPDpatients with AF, as compared to patients without AF (57 +/- 11 vs 44 +/- 7 ms, P = 0.001). In logistic regression analysis PWd was found to be the only factor associated with the development of AF (P = 0.04). CONCLUSIONS: The presence of AF was significantly related to the prolongation of PWd, but not with pulmonary function, arterial blood gasses, and left and right atrial function.
Authors: N Ozer; K Aytemir; E Atalar; E Sade; S Aksöyek; K Ovünç; T Açýl; N Nazlý; F Ozmen; A Oto; S Kes Journal: Pacing Clin Electrophysiol Date: 2000-11 Impact factor: 1.976
Authors: Geoffrey E J Seaborn; Keith Todd; Kevin A Michael; Adrian Baranchuk; Hoshiar Abdollah; Christopher S Simpson; Selim G Akl; Damian P Redfearn Journal: Ann Noninvasive Electrocardiol Date: 2013-09-24 Impact factor: 1.468
Authors: James E Tisdale; Matthew R Allen; Brian R Overholser; Heather A Jaynes; Richard J Kovacs Journal: J Cardiovasc Electrophysiol Date: 2015-03-31
Authors: Jared W Magnani; Michael J Mazzini; Lisa M Sullivan; MaryAnn Williamson; Patrick T Ellinor; Emelia J Benjamin Journal: Ann Noninvasive Electrocardiol Date: 2010-01 Impact factor: 1.468